Indivior Pharmaceuticals, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 82/100
What the filing says
Indivior reported Q3 2026 total net revenue of $356M (up 13% YoY) and SUBLOCADE revenue of $267M (up 22% YoY), with record net income of $137M and adjusted EBITDA of $211M (up 76% YoY). The company completed shareholder approval for its all-stock merger of equals with Supernus Pharmaceuticals, expected to close November 2, 2026; the combined entity will operate as Supernus under ticker SUPN. Indivior declared a special contingent cash dividend contingent on merger closing and ended Q3 with $332M in cash and investments.
Why this rating
Merger closing is material (relative to $1.8B market cap) and transformational, but already announced and approved. Strong financial performance offset by near-term integration uncertainty post-close.
Price action (we called it neutral)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.